Gamma-aminobutryic acid (GABA) is a major neurotransmitter in the central nervous system, and plasma levels of GABA may reflect brain GABA activity. In 35-40% of patients with mood disorders, plasma GABA levels are low compared to psychiatrically normal controls.
Of all brain neurotransmitters, perhaps ␥-aminobutyric acid (GABA) is the most ubiquitous, accounting for 30-50% of brain neurons and synapses. While GABA has traditionally been thought an 'inhibitory' neurotransmitter, new research has expanded this notion to the concept of disinhibition, since most GABA synapses are on other GABA neurons. 4 Thus, anatomically and functionally, GABA has been of increasing interest to behavioral scientists.
Psychiatric interest in GABA began in the late 1970s, when it was clinically observed that the mixed GABA agonist valproate was an effective agent for bipolar illness. 5 Confirmation of an important role for GABA in the depressive phase of manic-depressive illness ensued from the robust and well replicated demonstration of thymoleptic potency for alprazolam, an agonist at the GABA-A receptor. 6 Also, the newer anticonvulsants such as ␥-vinylGABA and gabapentin, with primary activity at the GABA system, 7 have increasing utility in treating patients with mood disorders, though complete documentation regarding their spectrum of therapeutic efficacy is pending. Thus, psychopharmacology supports a role for GABA in the pathophysiology of mood disorders.
Our research with plasma GABA 1 confirmed findings of low GABA in cerebrospinal fluid of depressed individuals. 8 This was then extended to bipolar disorder, where low plasma GABA characterizes both manic and depressive poles of illness, 9 proving that plasma GABA is not a state or phase marker. Additional research showed plasma GABA to be stable over a 4-year followup. 10 Further, low plasma GABA does not correlate with severity or duration of mood disorder. 1 Hence, low plasma GABA meets most criteria for a stable biological marker of mood disorders, albeit in only a subset of 30-50% of cases. About 30% of persons with alcohol dependence also have low GABA, and this persists for at least 6 months after sobriety. 2 Thus, low GABA is not specific to mood disorders, but seen in alcohol addiction, a condition linked to mood disorders both phenomenologically and genetically. 11 However, low GABA has some specificity as a biological marker, since this condition is not seen in schizophrenia, anxiety disorders, eating disorders, or conduct disorders. 12 Curious about whether plasma GABA could be a useful predictor for vulnerability, we decided to study whether it is a heritable component in family transmission. We studied this question in a series of families ascertained via probands from the Dallas VA mood disorders clinic.
The sample consisted of 83 males and 74 females ranging in age from 18 to 59. Mean GABA levels in the entire sample were 113 ng ml −1 (median value 108 ng ml −1 , standard deviation 33.6, range 53-329). The skewness of the sample was 1.98. Normality of the sample was assessed by means of the KolmogorovSmirnoff test, which failed to reject the null hypothesis of normality (P = 0.42). No transformations of the data were therefore undertaken.
Both the mean values and the variances of plasma GABA levels differed as a function of gender. Female values were significantly higher (female mean = 122, male mean = 104, t 155 = 3.45, P Ͻ 0.001) and more variable (female standard deviation = 38.1, male standard deviation = 26.5, F 73,82 = 2.06, P Ͻ 0.001) than males. Sex-specific parameters were therefore included in the analysis.
The parent-offspring correlation in the raw data was 0.12 (n = 101), and the sib-sib correlation was 0.15 (n = 73), neither of which was statistically significant (P Ͼ 0.1).
Results of the segregation analysis are summarized in Table 1 . The hypothesis of Mendelian transmission is highly significant when compared to a model of familial correlations ( model is compatible with the data ( The data in this sample are consistent with the existence of a recessive major gene regulating levels of plasma GABA in this population of persons identified with a proband who was diagnosed with unipolar depression. This model predicts that this gene occurs in the population with a frequency of 22%, and accounts for approximately 30% of the total variance in males and 35% of the total variance in females. Although this is consistent with the existence of a major gene controlling plasma GABA levels, these results do not conclusively demonstrate Mendelian transmission, since we could not reject the hypothesis of no transmission of a major effect. In other words, our data suggest that plasma GABA levels are either not genetic, or, if genetic, controlled by a single, major gene, inherited in a Mendelian recessive manner. However, it should be noted that the level of significance (P = 0.07) in failing to reject the recessive model is considered a 'trend' in some applications, and thus, perhaps not a robust finding. Additional research, with a larger sample size, should clarify this issue.
There are several limitations of this study. First, there was a significant amount of skewness in the raw data, making false inference of a major gene a possibility. However, a log transform of the data, which reduced the skewness to 0.28, produced identical results to this analysis.
Second, it is not clear whether residual family correlations are necessary in the final model to explain the familial distribution of plasma GABA. We observed a strongly negative residual FM , which was unexpected given the lack of correlation in the raw data. The residual correlation may be the result of potentially important covariates which were unaccounted for in this analysis.
Third, despite experimenting with different start values, estimates of transmission parameters in several models hit boundary values, reflecting a relatively flat likelihood surface. Our sample, consisting of primarily nuclear families, may not have had adequate power to estimate transmission parameters.
Fourth, we did not control for menstrual status in women in this preliminary study. Recent evidence suggests that plasma GABA levels vary during the menstrual cycle, 13 possibly reflecting modulation of GABA systems by neurosteroids. Future research should control for menstrual cycle phase in plasma GABA measurements.
The precise source of plasma GABA is not known. Considerable evidence, albeit indirect, suggests that levels of GABA in plasma reflect brain GABA concentrations or activity. 9 Clearly, though most GABA (95-98%) is located in the CNS, there are detectable amounts of GABA in some peripheral tissue, such as pancreas, ovaries, and testis CNA.
14 The extent to which peripheral sources of GABA contribute to plasma GABA awaits further research. Nevertheless, the correlations between plasma GABA and behavior and psychopathology suggest that plasma GABA is relevant to brain function, regardless of precise origin.
Single gene control is compatible with the fact that there are few mechanisms regulating extracellular GABA.
14 In future research, we hope to extend this finding by establishing the epidemiological covariates of plasma GABA and establishing the mode of familial transmission. Future research should also address the precise mechanism(s) which may account for the abnormality in GABA levels seen in the subset of patients with mood disorders and alcohol addiction.
Lack of replication is a problem that has plagued most studies in psychiatric genetics. Ultimately, confirmation of the present finding, as is the case for all studies in psychiatric genetics in general, will rest not only on robustly significant P-values, but also in replication in an independent sample. Caution should be exercised in the interpretation of these preliminary findings.
Methods
Families were included for study on the basis of a proband with a current episode of unipolar Major Depressive Disorder, single or recurrent. Probands were recruited from a Veterans Affairs mood disorders clinic in Texas. Spouses and first-degree relatives of study probands were then approached for participation in the study. All study subjects were diagnosed on the basis of the Structured Clinical Interview for DSM-III-R. All study subjects were medication free at the time of blood draw. Fasting plasma samples were drawn between 8 and 10 am, and GABA levels determined by HPLC. 2 In all, 157 subjects from 50 nuclear families were recruited for study.
Segregation analysis was conducted using the regressive models as implemented in the SAGE computer package (1994 version, Release 2.2, Case Western Reserve University, Cleveland, OH, USA).
We used the class D model that assumes equal correlation among siblings. Parameters for the class D model are q, the allele frequency, the three sex-specific genotypic means AA , AB , and BB , the three transmission probabilities AA , AB , and BB , the sex-specific residual variance 2 , and the residual family correlations PO (parent-offspring) and SS (sib-sib). All hypotheses were tested by means of the likelihood ratio criterion.
